Ovarian Cancer Drug Combo Showed Long-Term Survival
Patients with recurrent ovarian cancer saw an overall survival rate of 48% at three years in a new clinical study.
Updated on Oct. 3, 2026 in Cancer
Live Poll
Do you trust that new experimental immunotherapy treatments will lead to better long-term survival outcomes?
A clinical trial of the combination treatment botensilimab and balstilimab has reported three-year survival data for patients with recurrent ovarian cancer. The findings offer a potential look at outcomes for those who have exhausted standard therapy options.
Why it matters
Recurrent ovarian cancer often lacks effective standard treatments, making long-term survival data crucial for informing patient care decisions. This trial provides evidence for a new therapeutic approach for individuals with limited options.
In a clinical trial of 44 patients with heavily pretreated recurrent ovarian cancer, the combination of botensilimab and balstilimab demonstrated a 48% three-year overall survival estimate. Results were stable between years two and three, with a median overall survival of 14.8 months.
The players
Agenus
A biotechnology company focused on the development of immunotherapy treatments for cancer.
International Gynecologic Cancer Society
A professional organization that facilitates global research and education for gynecologic cancers.
The details
The treatment combines botensilimab, an immune-modulating agent, with balstilimab, an anti-PD-1 antibody, to help the immune system identify and attack cancer cells. By targeting two different pathways, the combination aims to overcome resistance in patients who have already received a median of four prior lines of therapy. Nearly three-quarters of the study population had platinum-resistant or refractory disease, representing a group that typically faces significant challenges in treatment response.
Timeline
December 13, 2025: Data cutoff for the analysis.
October 3, 2026: Results presented at the International Gynecologic Cancer Society Annual Global Meeting.
Health Landscape
These results represent an ongoing attempt to expand the immunotherapy pipeline for platinum-resistant ovarian cancer, a condition where standard options are historically limited. The findings mark a departure from single-agent therapies by utilizing a dual-action approach to target advanced disease.
This study highlights potential options for those with recurrent ovarian cancer who have exhausted standard treatments. Patients and their families should have a conversation with an oncologist about whether clinical trials involving immunotherapy combinations are appropriate for their specific case.
The takeaway
While survival outcomes for heavily pretreated recurrent ovarian cancer remain complex, this combination therapy showed 25% of participants remained alive and off all treatments. Discuss the suitability of emerging immunotherapy combinations with a specialist as part of long-term care planning.
Further reading
For broader context on current clinical advancements, explore the latest research in the Cancer section.
More information
Access the full study documentation via the Agenus publications and presentation portal.
Live Poll
Do you trust that new experimental immunotherapy treatments will lead to better long-term survival outcomes?
